Neurogene Sponsors Invitae’s No-Charge Genetic Testing Program for Suspected Lysosomal Disease Patients
qimono / Pixabay

Neurogene Sponsors Invitae’s No-Charge Genetic Testing Program for Suspected Lysosomal Disease Patients

According to a press release from American biotechnology company Neurogene, the Company has kicked off a sponsorship of Invitae Corporation's "Detect Lysosomal Storage Diseases" program, which will offer genetic testing…

Continue Reading Neurogene Sponsors Invitae’s No-Charge Genetic Testing Program for Suspected Lysosomal Disease Patients

This Young Man Accurately Diagnosed His Own Disorder But Doctors Did Not Believe His Diagnosis

Doug Lindsay ran track in high school. According to an article published by CNN Health, Doug had big plans as a senior at Rockhurst University in Kansas City where he…

Continue Reading This Young Man Accurately Diagnosed His Own Disorder But Doctors Did Not Believe His Diagnosis

Bladder Cancer Drug That Received Accelerated Approval Shows Even Stronger Findings in Later Study

According to a publication from Medscape, the first ever drug targeted for bladder cancer has shown even more impressive results in post-approval study. Erdafitinib was approved on an accelerated basis…

Continue Reading Bladder Cancer Drug That Received Accelerated Approval Shows Even Stronger Findings in Later Study

A Brief Discussion of How Cell and Gene Therapies are Being Improved for Future Generations

  While the last few years have seen major advances in all areas of the pharmaceutical industry, some of the newest and brightest talents are now focusing on cell and…

Continue Reading A Brief Discussion of How Cell and Gene Therapies are Being Improved for Future Generations
When the Latest Treatments are Out of Reach, Familial Hypercholesterolemia Patients Suffer
geralt / Pixabay

When the Latest Treatments are Out of Reach, Familial Hypercholesterolemia Patients Suffer

According to a story from FHM Pakistan, a recent study revealed the familial hypercholesterolemia patients are at a greater risk of stroke, heart attack, and other cardiovascular problems when they…

Continue Reading When the Latest Treatments are Out of Reach, Familial Hypercholesterolemia Patients Suffer

FDA Agrees to Priority Review of Epithelial Sarcoma Drug Candidate Tazemetostat

According to a publication from Specialty Pharma Times, the American Food and Drug Administration (FDA) has granted priority review to Tazemetostat, Epizyme, Inc's epithelioid sarcoma drug candidate. About Epithelioid Sarcoma…

Continue Reading FDA Agrees to Priority Review of Epithelial Sarcoma Drug Candidate Tazemetostat
Close Menu